It's not currently possible to cure spinal muscular atrophy (SMA), but research is ongoing to find new treatments.
Treatment and support is available to manage the symptoms and help people with the condition have the best possible quality of life.
A team of different healthcare professionals will be involved in your or your child's care. They'll help come up with a care plan outlining the support and treatments you may need.
It's important for people with SMA, especially children, to get the right nutrients. This will help with healthy growth and development.
A dietitian can offer advice about feeding and diet.
If you or your child has difficulty feeding or swallowing, a feeding tube may sometimes be needed.
Several types of tube can be used, such as a tube attached directly to the stomach through the skin of the tummy (gastrostomy tube), or a tube passed through the nose and down the throat (nasogastric tube).
There are several treatments for the breathing problems that can affect people with SMA.
You may be advised to have vaccinations against flu and pneumonia to reduce your risk of becoming seriously ill from these infections.
If you or your child have difficulty moving, an Occupational Therapist or Physiotherapist can provide advice and support.
For example, they can advise you about things such as:
Exercises and stretches can help maintain strength and stop joints becoming stiff.
A Physiotherapist can suggest some exercises to try.
The amount of exercise you or your child can do will depend on your condition, but it's best to try to stay as active as possible.
Some children with SMA develop an unusually curved spine (scoliosis).
Treatments for this include:
Research is being carried out into possible new treatments for SMA.
You can ask your medical team about ongoing clinical trials into new treatments. You can also check the database of clinical trials for SMA to see what research is happening at the moment.
Previous research has suggested a new medicine called nusinersen (Spinraza) can help some people with SMA.
It was recently approved in the US and by the European Medicines Agency, but will be assessed by the National Institute for Health and Care Excellence (NICE) before it can be made routinely available in England.
For more information, see: